Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: Observations in animals and humans

Circulation

Volumn 95, Issue 7, 1997, Pages 1755-1759

  Gold, Herman K ^a   Garabedian, Harry D ^a   Dinsmore, Robert E ^a   Guerrero, Luis J ^a   Cigarroa, Joaquin E ^a   Palacios, Igor F ^a   Leinbach, Robert C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

7E3; myocardial infarction; platelet aggregation inhibitors; reperfusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN; PLASMINOGEN ACTIVATOR; THROMBIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY THROMBOSIS; DOG; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030998690     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.7.1755     Document Type: Article

References (20)

1. Friedman MF, Van der Bovenkamp EJ. The pathogenesis of a coronary thrombus. Am J Pathol. 1966;48:19-44.
2. Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79:920-928.
3. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis. J Am Coll Cardiol. 1989; 13:1409-1414.
4. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988;77: 670-677.
5. Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb. 1993;13:1837-1842.
6. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromboasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-338.
7. Jordan RE, Knight DM, Wagner C, McAleer MF, McDonough M, Mattis JA, Coller BS, Weisman HF, Ghrayeb J. A dramatic reduction of the immunogenicity of the anti-GPIIb/IIIa monoclonal antibody, 7E3 Fab, by humanization of the murine constant domains. Circulation. 1992;86(suppl I):I-411. Abstract.
8. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest. 1988;81:1284-1291.
9. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888.
10. Braunwald E. Myocardial reperfusion, limitations of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation. 1989;79:441-444.
11. The TIMI Study Group. The Thrombolysis In Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312: 932-936.
12. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) phase II trial. N Engl J Med. 1989;320:617-628.
13. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neil WW. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993;328:673-679.
14. The GUSTO-I Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
15. Shatos MA, Doherty JM, Garabedian HD, Gold HK. ReoPro, antiplatelet antibody, enhances fibrinolytic potential of cultured arterial microvascular cells. Circulation. 1996;94(suppl I):I-702. Abstract.
16. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis.' J Clin Invest. 1996;98:863-874.
17. Wharton TP, McNamara NS, Schmitz JM, Felese FA, Jacobs MI, Gladstone AR, Funk EJ, Corbett P. Early coronary patency after high-dose heparin without thrombolytic therapy in 158 patients with acute myocardial infarction. Circulation. 1996;94(suppl I):I-553. Abstract.
18. Verbeugt FWA, Marsh RC, Veen G, Galijee MA, de Cock CC, Bronzwaer JGF. High-dose bolus heparin alone as primary reperfusion therapy for acute transmural myocardial infarction: preliminary results of the ongoing angiographic HEAP pilot study. Circulation. 1994;90(suppl I):I-563. Abstract.
19. Esteves FP, Braga JC, Latado A, Azevedo A Jr, Brito JC, Godinho AG, Rocha MS, Rabelo A Jr, Esteves JP. Confirmation that heparin is an alternative to promote early reperfusion in acute myocardial infarction: the CHEAPER study. Circulation. 1996; 94(suppl I):I-553. Abstract.
20. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.